In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer Publisher Pubmed

Alibolandi M¹ ; Ramezani M^{2, 3} ; Abnous K² ; Sadeghi F^{4, 5} ; Atyabi F⁶ ; Asouri M⁷ ; Ahmadi AA⁷ ; Hadizadeh F¹

Source: Journal of Controlled Release Published:2015

Abstract

Targeted, disease-specific delivery of therapeutic nanoparticles shows wonderful promise for transmitting highly cytotoxic anti-cancer agents. Using the reaction of non-small cell lung cancer (SK-MES-1 and A549 cell lines) as representative of other cancer types', the present study examines the effects of EpCAM-fluoropyrimidine RNA aptamer-decorated, DOX-loaded, PLGA-b-PEG nanopolymersomes that bond specifically to the extracellular domain of epithelial-cell adhesion molecules. Results demonstrate that EpCAM aptamer-conjugated DOX-NPs (Apt-DOX-NP) significantly enhance cellular nanoparticle uptake in SK-MES-1 and A549 cell lines and increase the cytotoxicity of the DOX payload as compared with non-targeted DOX-NP (P < 0.05). Additionally, Apt-DOX-NP exhibits greater tumor inhibition in nude mice bearing SK-MES-1 non-small cell lung-cancer xenografts and reduces toxicity, as determined by loss of body weight, cardiac histopathology and animal survival rate in vivo. After a single intravenous injection of Apt-DOX-NP and DOX-NPs, tumor volume decreased 60.9% and 31.4%, respectively, in SK-MES-1-xenograft nude mice compared with members of a saline-injected control group. This study proves the potential utility of Apt-DOX-NP for therapeutic application in non-small cell lung cancer. In the future, EpCAM-targeted therapies might play a key role in treating non-small cell lung cancer, the most common type of lung cancer. © 2015 Elsevier B.V.

Related Docs

View other Related Docs

1. The Chemotherapeutic Potential of Doxorubicin-Loaded Peg-B-Plga Nanopolymersomes in Mouse Breast Cancer Model, European Journal of Pharmaceutics and Biopharmaceutics (2015)

2. Recent Advancements in Aptamer-Bioconjugates: Sharpening Stones for Breast and Prostate Cancers Targeting, Journal of Drug Delivery Science and Technology (2019)

3. Does Pharmacodynamics of Drugs Change After Presenting Them As Na-Noparticles Like Their Pharmacokinetics?, Current Drug Targets (2020)

Experts (# of related papers)

View all Related Experts

Fatemeh Atyabi (5)

Rassoul Dinarvand (3)

Other Related Docs

4. Targeting, Bio Distributive and Tumor Growth Inhibiting Characterization of Anti-Her2 Affibody Coupling to Liposomal Doxorubicin Using Balb/C Mice Bearing Tubo Tumors, International Journal of Pharmaceutics (2016)

5. Improved Drug Delivery and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin by Targeting Anti-Her2 Peptide in Murine Breast Tumor Model, European Journal of Pharmaceutical Sciences (2016)

6. Nanoparticles and Targeted Drug Delivery in Cancer Therapy, Immunology Letters (2017)

7. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and Igf-1R Sirna to Skbr3 Metastatic Breast Cancer Cells, Iranian Biomedical Journal (2019)

8. Aptamer Hybrid Nanocomplexes As Targeting Components for Antibiotic/Gene Delivery Systems and Diagnostics: A Review, International Journal of Nanomedicine (2020)

9. Nanovehicles for Co-Delivery of Anticancer Agents, Drug Discovery Today (2020)

10. Targeted Delivery of Doxorubicin by Sp5-52 Peptide Conjugated Exosome Nanoparticles Into Lung Tumor: An in Vitro and in Vivo Study, Journal of Drug Delivery Science and Technology (2024)

11. Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody, Artificial Cells# Nanomedicine and Biotechnology (2018)

12. 5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells, Artificial Cells# Nanomedicine and Biotechnology (2018)

13. Antibody Based Epcam Targeted Therapy of Cancer, Review and Update, Current Cancer Drug Targets (2018)

14. Specific Cellular Internalization and Ph-Responsive Behavior of Doxorubicin Loaded Plga-Peg Nanoparticles Targeted With Anti Egfrviii Antibody, Life Sciences (2020)

15. Functionalized Nanoscale Β-1,3-Glucan to Improve Her2 + Breast Cancer Therapy: In Vitro and in Vivo Study, Journal of Controlled Release (2015)

16. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)

17. Engineered (Nh2)-Mil-125(Ti)/Copolymer@Mnfe2o4 Nanocomposite for Synergistic Eradication of Cancer Cells Via Dox/Pcrispr Delivery, Advanced Composites and Hybrid Materials (2024)

18. Trimethyl-Chitosan Coated Gold Nanoparticles Enhance Delivery, Cellular Uptake and Gene Silencing Effect of Egfr-Sirna in Breast Cancer Cells, Frontiers in Molecular Biosciences (2022)

19. Emerging Innovations in Vincristine-Encapsulated Nanoparticles: Pioneering a New Era in Oncological Therapeutics, Journal of Drug Delivery Science and Technology (2024)

20. Immunogenicity of Different Types of Adjuvants and Nano-Adjuvants in Veterinary Vaccines: A Comprehensive Review, Vaccines (2023)

Style	Citing Format
MLA	Alibolandi M, et al.. "In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer." Journal of Controlled Release, vol. 209, no. , 2015, pp. 88-100.
APA	Alibolandi M, Ramezani M, Abnous K, Sadeghi F, Atyabi F, Asouri M, Ahmadi AA, Hadizadeh F (2015). In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer. Journal of Controlled Release, 209(), 88-100.
Chicago	Alibolandi M, Ramezani M, Abnous K, Sadeghi F, Atyabi F, Asouri M, Ahmadi AA, Hadizadeh F. "In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer." Journal of Controlled Release 209, no. (2015): 88-100.
Harvard	Alibolandi M et al. (2015) 'In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer', Journal of Controlled Release, 209(), pp. 88-100.
Vancouver	Alibolandi M, Ramezani M, Abnous K, Sadeghi F, Atyabi F, Asouri M, et al.. In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer. Journal of Controlled Release. 2015;209():88-100.
BibTex	@article{ author = {Alibolandi M and Ramezani M and Abnous K and Sadeghi F and Atyabi F and Asouri M and Ahmadi AA and Hadizadeh F}, title = {In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer}, journal = {Journal of Controlled Release}, volume = {209}, number = {}, pages = {88-100}, year = {2015} }
RIS	TY - JOUR AU - Alibolandi M AU - Ramezani M AU - Abnous K AU - Sadeghi F AU - Atyabi F AU - Asouri M AU - Ahmadi AA AU - Hadizadeh F TI - In Vitro and in Vivo Evaluation of Therapy Targeting Epithelial-Cell Adhesion-Molecule Aptamers for Non-Small Cell Lung Cancer JO - Journal of Controlled Release VL - 209 IS - SP - 88 EP - 100 PY - 2015 ER -

Science Communicator Platform

Authors

Abstract